Retina Implant gains approval for extended European clinical trials

Article

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

The trial commenced in Tübingen, Gemany in 2010. The multicentre phase of Retina Implant's second human clinical trial will take place in Germany, Budapest, London and Oxford. The study involves patients keeping the implant in permanently so it can be used in everyday situations.

Nine patients were implanted with Retina Implant's wireless device between May 2010 and July 2011. The findings saw patients presenting with the best visual acuity recorded so far. The majority of patients experienced restored vision for everyday life. Visual perception in dim and bright environments was achieved in a significant number of patients.

Professor MacLaren, professor of ophthalmology at Oxford University Hospitals NHS Trust, said, "We are delighted to be involved in testing this pioneering subretinal implant technology. The results achieved by the Retina Implant team to-date represent a significant advance in this technology that could greatly enhance the quality of life for people with an incurable, blinding disease."

Dr Walter G. Wrobel, CEO of Retina Implant, said, "We are pleased that after reviewing the results of the first nine patients in the trial, the scientific advisory board is in agreement that the next stage of our research should begin. The Board's continued support reinforces the progress Retina Implant continues to make on our journey to permanently restore useful vision to retinitis pigmentosa patients."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.